Publications 2021

Syversen SW, Goll GL, Jorgensen KK, Sandanger O, Sexton J, Olsen IC, Gehin JE, Warren DJ, Brun MK, Klaasen RA, Karlsen LN, Noraberg G, Zettel C, Ljosa MKA, Haugen AJ, Njalla RJ, Bruun TJ, Seeberg KA, Michelsen B, Strand EK, Skorpe S, Blomgren IM, Bragnes YH, Dotterud CK, Thune T et al. (2021)
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases A Randomized Clinical Trial
JAMA-J. Am. Med. Assoc., 325 (17), 1744-1754
DOI 10.1001/jama.2021.4172

Syversen SW, Jorgensen KK, Goll GL, Brun MK, Sandanger O, Bjorlykke KH, Sexton J, Olsen IC, Gehin JE, Warren DJ, Klaasen RA, Noraberg G, Bruun TJ, Dotterud CK, Ljosa MKA, Haugen AJ, Njalla RJ, Zettel C, Ystrom CM, Bragnes YH, Skorpe S, Thune T, Seeberg KA, Michelsen B, Blomgren IM et al. (2021)
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases A Randomized Clinical Trial
JAMA-J. Am. Med. Assoc., 326 (23), 2375-2384
DOI 10.1001/jama.2021.21316

Publications 2020

Niyonzima N, Bakke SS, Gregersen I, Holm S, Sandanger O, Orrem HL, Sporsheim B, Ryan L, Kong XY, Dahl TB, Skjelland M, Sorensen KK, Rokstad AM, Yndestad A, Latz E, Gullestad L, Andersen GO, Damas JK, Aukrust P, Mollnes TE, Halvorsen B, Espevik T (2020)
Cholesterol crystals use complement to increase NLRP3 signaling pathways in coronary and carotid atherosclerosis
EBioMedicine, 60, 102985
DOI 10.1016/j.ebiom.2020.102985

Syversen SW, Goll GL, Jorgensen KK, Olsen IC, Sandanger O, Gehin JE, Warren DJ, Sexton J, Mork C, Jahnsen J, Kvien TK, Bolstad N, Haavardsholm EA (2020)
Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)
Trials, 21 (1), 13
DOI 10.1186/s13063-019-3734-4

Publications 2019

Torp MK, Yang K, Ranheim T, Lauritzen KH, Alfsnes K, Vinge LE, Aukrust P, Stenslokken KO, Yndestad A, Sandanger O (2019)
Mammalian Target of Rapamycin (mTOR) and the Proteasome Attenuates IL-1 beta Expression in Primary Mouse Cardiac Fibroblasts
Front. Immunol., 10, 1285
DOI 10.3389/fimmu.2019.01285

Yang K, Lauritzen KH, Olsen MB, Dahl TB, Ranheim T, Ahmed MS, Attramadal H, Aukrust P, Halvorsen B, Nyman TA, Sandanger O, Yndestad A (2019)
Low Cellular NAD(+) Compromises Lipopolysaccharide-Induced Inflammatory Responses via Inhibiting TLR4 Signal Transduction in Human Monocytes
J. Immunol., 203 (6), 1598-1608
DOI 10.4049/jimmunol.1801382

Publications 2017

Dhondup Y, Sjaastad I, Sandanger O, Aronsen JM, Ahmed MS, Attramadal H, Finsen AV, Zhang LL, Ranheim T, Alfsnes K, Aukrust P, Christensen G, Yndestad A, Vinge LE (2017)
Toll-Like Receptor 9 Promotes Survival in SERCA2a KO Heart Failure Mice
Mediat. Inflamm., 2017, 9450439
DOI 10.1155/2017/9450439

Gregersen I, Sandanger O, Askevold ET, Sagen EL, Yang K, Holm S, Pedersen TM, Skjelland M, Krohg-Sorensen K, Hansen TV, Dahl TB, Otterdal K, Espevik T, Aukrust P, Yndestad A, Halvorsen B (2017)
Interleukin 27 is increased in carotid atherosclerosis and promotes NLRP3 inflammasome activation
PLoS One, 12 (11), e0188387
DOI 10.1371/journal.pone.0188387

Sokolova M, Vinge LE, Alfsnes K, Olsen MB, Eide L, Kaasboll OJ, Attramadal H, Torp MK, Fosshaug LE, Rashidi A, Lien E, Finsen AV, Sandanger O, Aukrust P, Ranheim T, Yndestad A (2017)
Palmitate promotes inflammatory responses and cellular senescence in cardiac fibroblasts
Biochim. Biophys. Acta Mol. Cell Biol. Lipids, 1862 (2), 234-245
DOI 10.1016/j.bbalip.2016.11.003

Publications 2016

Dhondup Y, Ueland T, Dahl CP, Askevold ET, Sandanger O, Fiane A, Ohm IK, Sjaastad I, Finsen AV, Waehre A, Gullestad L, Aukrust P, Yndestad A, Vinge LE (2016)
Low Circulating Levels of Mitochondrial and High Levels of Nuclear DNA Predict Mortality in Chronic Heart Failure
J. Card. Fail., 22 (10), 823-828
DOI 10.1016/j.cardfail.2016.06.013

Sandanger O, Gao E, Ranheim T, Bilksoen M, Kaasboll OJ, Alfnes K, Nymo SH, Rashidi A, Ohm IK, Attramadal H, Aukrust P, Vinge LE, Yndestad A (2016)
NLRP3 inflammasome activation during myocardial ischemia reperfusion is cardioprotective
Biochem. Biophys. Res. Commun., 469 (4), 1012-1020
DOI 10.1016/j.bbrc.2015.12.051

Yndestad A, Sandanger O, Jong WMC, Aukrust P, Zuurbier CJ (2016)
Response to letter from Toldo et al. on "NLRP3 inflammasome activation during myocardial ischemia reperfusion is cardioprotective"
Biochem. Biophys. Res. Commun., 474 (2), 328-329
DOI 10.1016/j.bbrc.2016.04.096

Publications 2015

Dhondup Y, Sjaastad I, Scott H, Sandanger O, Zhang LL, Haugstad SB, Aronsen JM, Ranheim T, Holmen SD, Alfsnes K, Ahmed MS, Attramadal H, Gullestad L, Aukrust P, Christensen G, Yndestad A, Vinge LE (2015)
Sustained Toll-Like Receptor 9 Activation Promotes Systemic and Cardiac Inflammation, and Aggravates Diastolic Heart Failure in SERCA2a KO Mice
PLoS One, 10 (10), e0139715
DOI 10.1371/journal.pone.0139715

Publications 2014

Huber-Lang M, Barratt-Due A, Pischke SE, Sandanger O, Nilsson PH, Nunn MA, Denk S, Gaus W, Espevik T, Mollnes TE (2014)
Double Blockade of CD14 and Complement C5 Abolishes the Cytokine Storm and Improves Morbidity and Survival in Polymicrobial Sepsis in Mice
J. Immunol., 192 (11), 5324-5331
DOI 10.4049/jimmunol.1400341

Ohm IK, Alfsnes K, Olsen MB, Ranheim T, Sandanger O, Dahl TB, Aukrust P, Finsen AV, Yndestad A, Vinge LE (2014)
Toll-Like Receptor 9 Mediated Responses in Cardiac Fibroblasts
PLoS One, 9 (8), e104398
DOI 10.1371/journal.pone.0104398

Publications 2013

Sandanger O, Ranheim T, Vinge LE, Bliksoen M, Alfsnes K, Finsen AV, Dahl CP, Askevold ET, Florholmen G, Christensen G, Fitzgerald KA, Lien E, Valen G, Espevik T, Aukrust P, Yndestad A (2013)
The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemiareperfusion injury
Cardiovasc. Res., 99 (1), 164-174
DOI 10.1093/cvr/cvt091

Sandanger O, Ranheim T, Vinge LE, Bliksoen M, Valen G, Aukrust P, Yndestad A (2013)
A role for NLRP3 inflammasome in acute myocardial ischaemia-reperfusion injury? Reply
Cardiovasc. Res., 99 (1), 226-227
DOI 10.1093/cvr/cvt130

Publications 2012

Orn S, Ueland T, Manhenke C, Sandanger O, Godang K, Yndestad A, Mollnes TE, Dickstein K, Aukrust P (2012)
Increased interleukin-1 beta levels are associated with left ventricular hypertrophy and remodelling following acute ST segment elevation myocardial infarction treated by primary percutaneous coronary intervention
J. Intern. Med., 272 (3), 267-276
DOI 10.1111/j.1365-2796.2012.02517.x

Yndestad A, Finsen AV, Ueland T, Husberg C, Dahl CP, Oie E, Vinge LE, Sjaastad I, Sandanger O, Ranheim T, Dickstein K, Kjekshus J, Damas JK, Fiane AE, Hilfiker-Kleiner D, Lipp M, Gullestad L, Christensen G, Aukrust P (2012)
The Homeostatic Chemokine CCL21 Predicts Mortality and May Play a Pathogenic Role in Heart Failure
PLoS One, 7 (3), e33038
DOI 10.1371/journal.pone.0033038

Publications 2011

Grimstad O, Sandanger O, Ryan L, Otterdal K, Damaas JK, Pukstad B, Espevik T (2011)
Cellular sources and inducers of cytokines present in acute wound fluid
Wound Repair Regen., 19 (3), 337-347
DOI 10.1111/j.1524-475X.2011.00668.x

Publications 2009

Sandanger O, Ryan L, Bohnhorst J, Iversen AC, Husebye H, Halaas O, Landro L, Aukrust P, Froland SS, Elson G, Visintin A, Oktedalen O, Damas JK, Sundan A, Golenbock D, Espevik T (2009)
IL-10 Enhances MD-2 and CD14 Expression in Monocytes and the Proteins Are Increased and Correlated in HIV-Infected Patients
J. Immunol., 182 (1), 588-595
DOI 10.4049/jimmunol.182.1.588

Publications 2006

Husebye H, Halaas O, Stenmark H, Tunheim G, Sandanger O, Bogen B, Brech A, Latz E, Espevik T (2006)
Endocytic pathways regulate Toll-like receptor 4 signaling and link innate and adaptive immunity
Embo J., 25 (4), 683-692
DOI 10.1038/sj.emboj.7600991